pulmonari
arteri
hypertens
pah
chronic
lung
diseas
poor
diagnosi
limit
therapeut
option
current
avail
therapi
ineffect
improv
qualiti
life
reduc
mortal
rate
exist
clear
unmet
medic
need
treat
diseas
necessit
discoveri
novel
therapeut
targetsag
safe
success
therapi
alter
reninangiotensin
system
ra
implic
caus
factor
pathogenesi
pah
angiotensin
ii
ang
ii
key
effector
peptid
ra
exert
deleteri
effect
pulmonari
vasculatur
result
vasoconstrict
prolifer
inflamm
contribut
pah
develop
recent
new
member
ra
angiotensin
convert
enzym
discov
enzym
function
neg
regul
angiotensin
system
metabol
ang
ii
put
protect
peptid
angiotensin
abundantli
express
lung
tissu
emerg
evid
suggest
benefici
role
enzym
lung
diseas
review
focu
relat
pulmonari
hypertens
provid
proof
principl
therapeut
role
pah
pulmonari
arteri
hypertens
pah
debilit
chronic
disord
lung
character
sustain
elev
blood
pressur
pulmonari
vasculatur
normal
mean
pulmonari
arteri
pressur
healthi
adult
mm
hg
rest
howev
pah
rest
mean
pulmonari
arteri
pressur
measur
mm
hg
greater
mm
hg
exercis
pah
either
idiopath
origin
unknown
etiolog
aris
due
secondari
medic
condit
collagen
vascular
diseas
heart
malform
viral
infect
genet
epigenet
risk
factor
also
link
pah
pathogenesi
regardless
caus
pah
associ
endotheli
dysfunct
vasoconstrict
remodel
pulmonari
vessel
endotheli
dysfunct
believ
earli
compon
pulmonari
hypertens
process
creat
imbal
vasodil
nitric
oxid
prostacyclin
vasoconstrictor
substanc
endothelin
thromboxan
serotonin
imbal
lead
cascad
event
result
hyperprolifer
pulmonari
smooth
muscl
cell
activ
lung
fibroblast
induct
thrombot
mediat
releas
inflammatori
cytokin
increas
vascular
resist
pressur
one
causal
factor
endotheli
dysfunct
vascular
impair
reninangiotensin
system
ra
activ
classic
axi
ra
compris
angiotensin
convert
enzym
ace
vasoact
peptid
angiotensin
ii
ang
ii
receptor
advers
affect
pulmonari
hemodynam
caus
pah
convers
recent
discov
homologu
ace
shown
oppos
detriment
effect
axi
cardiopulmonari
system
review
focus
role
pathobiolog
pulmonari
hypertens
provid
proof
concept
target
enzym
prove
effect
therapeut
strategi
treatment
pah
ra
compos
seri
enzymat
reaction
lead
gener
sever
angiotensin
peptid
cascad
begin
proteolyt
cleavag
angiotensinogen
renin
yield
inact
precursor
angiotensin
angiotensin
act
upon
ace
form
ang
ii
biolog
activ
vasopeptid
mediat
effect
via
two
distinct
receptor
subtyp
stimul
caus
vasoconstrict
cell
prolifer
inflamm
fibrosi
activ
regul
oppos
effect
sever
new
member
ra
recent
identifi
expand
understand
biolog
system
new
member
includ
pro
renin
receptor
angiotensin
angiotensin
ma
receptor
major
compon
ra
includ
renin
angiotensinogen
ace
ma
receptor
express
lung
tissu
relev
point
polymorph
gene
encod
angiotensinogen
ace
link
develop
pah
regard
ace
gene
insertiondelet
polymorph
base
pair
intron
result
three
distinct
genotyp
dd
homozyg
delet
allel
ii
homozyg
insert
allel
id
heterozygot
delet
allel
dd
associ
increas
ace
activ
insert
allel
ii
associ
decreas
ace
activ
ace
dd
genotyp
accompani
elev
circul
level
ang
ii
implic
develop
pah
interestingli
lung
pulmonari
hypertens
patient
well
anim
pah
express
high
level
ace
suggest
caus
role
enzym
diseas
pathogenesi
ace
primari
enzym
respons
ang
ii
product
lung
ang
ii
peptid
potent
pulmonari
vasoconstrictor
mitogen
action
anim
clinic
studi
shown
stimul
pulmonari
smooth
muscl
cell
ang
ii
produc
migratori
hypertroph
prolif
effect
furthermor
ang
ii
initi
inflammatori
process
gener
cellular
reactiv
oxygen
speci
ro
factor
contribut
pathophysiolog
pah
accumul
evid
also
suggest
ang
ii
induc
apoptosi
lung
parenchym
cell
lead
pulmonari
hypertens
collect
find
clearli
indic
activ
role
ra
pulmonari
hypertens
process
howev
pharmacolog
blockad
ace
inhibitor
antagonist
produc
mix
result
pah
thu
render
medic
use
somewhat
controversi
nevertheless
sever
line
emerg
evid
strongli
suggest
recent
discov
ace
homologu
either
catalyt
product
ang
oppos
prolif
hypertroph
fibrot
effect
ang
ii
mani
organ
includ
lung
suggest
plausibl
protect
role
pah
discov
close
homologu
ace
decad
ago
two
independ
research
group
use
distinct
methodolog
contain
amino
acid
share
sequenc
homolog
activ
site
ace
howev
unlik
ace
dipeptidylpeptidas
monocarboxypeptidas
cleav
singl
amino
acid
ctermin
substrat
ang
ii
appear
main
substrat
effect
hydrolyz
angiotensin
ang
apelin
neurotensin
dynorphin
bradykinin
bradykinin
known
peptid
target
exist
membranebound
protein
lung
stomach
spleen
intestin
bonemarrow
kidney
liver
brain
particularli
lung
express
vascular
endothelium
type
type
ii
alveolar
epitheli
cell
smooth
muscl
cell
pulmonari
vasculatur
bronchial
epithelia
though
exist
primarili
membranebound
protein
solubl
form
detect
plasma
urin
contribut
lung
pathophysiolog
suggest
play
import
role
lung
pathophysiolog
evid
come
follow
observ
first
decreas
express
associ
lung
fibrosi
human
experiment
anim
second
lung
overexpress
attenu
monocrotalineinduc
pulmonari
hypertens
bleomycininduc
pulmonari
fibrosi
third
protect
murin
lung
acut
injuri
respiratori
distress
syndrom
fourth
mutant
mice
exhibit
enhanc
vascular
permeabl
declin
lung
function
fifth
reduc
pulmonari
express
due
sarscov
infect
result
lung
failur
sixth
administr
recombin
prevent
develop
lung
failur
knockout
mice
seventh
treatment
revers
establish
pah
mice
ja
johnson
et
al
abstract
j
respir
crit
care
med
recent
report
takahashi
et
al
also
suggest
autoantibodi
may
predispos
patient
connect
tissu
diseas
pah
observ
substanti
import
lung
pathophysiolog
remodel
right
ventricl
character
myocyt
hypertrophi
fibrosi
often
observ
pulmonari
hypertens
patient
earli
stage
pah
remodel
process
repres
adapt
respons
compens
increas
right
ventricular
workload
howev
time
right
ventricl
becom
thicken
enlarg
dysfunct
culmin
heart
failur
fact
right
ventricular
failur
primari
caus
death
patient
pah
zisman
et
al
first
investig
report
increas
activ
elev
angiotensin
level
ventricl
pah
patient
appear
upregul
subsequ
increas
ang
level
may
compensatori
respons
protect
tissu
injuri
view
support
sever
experiment
studi
wherein
administr
ang
exert
cardioprotect
effect
convers
defici
result
increas
incid
cardiac
death
due
chronic
pressur
overload
particular
relev
pulmonari
therapeut
lung
overexpress
prevent
develop
right
ventricular
hypertrophi
anim
model
pah
lung
fibrosi
figur
similar
benefici
effect
also
observ
endogen
activ
use
xnt
ethylamino
hydroxymethyl
sulfonyl
oxi
part
protect
mechan
may
relat
decreas
level
ang
ii
andor
ensu
increas
ang
besid
modul
matrix
metalloproteinas
mmp
especi
may
also
respons
antiremodel
effect
well
known
mmp
contribut
cardiac
remodel
pah
furthermor
overexpress
shown
inhibit
hypoxiainduc
collagen
product
cardiac
fibroblast
highlight
antifibrot
action
layer
pulmonari
vessel
wall
undergo
structur
function
chang
pah
chang
includ
prolifer
vascular
smooth
muscl
cell
intim
thicken
extens
smooth
muscl
previous
nonmuscular
arteriol
vascular
remodel
reduc
lumen
diamet
therebi
increas
pulmonari
vascular
resist
pressur
vitro
studi
shown
decreas
level
associ
hyperprolifer
enhanc
migrat
pulmonari
smooth
muscl
cell
suggest
vasoprotect
role
vitro
data
confirm
vivo
studi
wherein
lung
overexpress
prevent
vessel
wall
thicken
also
attenu
muscular
pulmonari
vessel
administr
xnt
synthet
activ
also
exert
similar
benefici
effect
pulmonari
vasculatur
experiment
model
pah
reduc
bioavail
increas
format
ro
inflamm
hallmark
pah
improv
aforement
factor
essenti
effect
pulmonari
hypertens
therapi
predominantli
local
vascular
endothelium
exert
vasodilatori
action
contrari
defici
impair
endotheliumdepend
vasorelax
cardiovascular
renal
exert
host
action
cardiopulmonari
system
includ
prevent
endotheli
dysfunct
reduct
pulmonari
oxid
stress
attenu
vascular
impair
antiinflammatori
anticardiac
remodel
effect
properti
respons
protect
role
pulmonari
arteri
hypertens
underscor
import
endotheli
function
stoichiometr
balanc
superoxid
critic
maintain
normal
vascular
tone
well
establish
ang
ii
increas
superoxid
product
upregul
endotheli
nicotinamid
adenin
dinucleotid
phosphat
oxidas
nadph
oxidas
result
vascular
impair
hand
shown
reduc
ang
ii
mediat
superoxid
product
therebi
improv
vascular
function
inflammatori
cytokin
eg
tnfa
growth
factor
tgfb
substanti
contribut
develop
andor
progress
pah
regard
treatment
xnt
shown
decreas
express
proinflammatori
cytokin
lung
also
decreas
proinflammatori
cytokin
level
accompani
concomit
increas
antiinflammatori
cytokin
taken
togeth
experiment
evid
indic
protect
role
endotheli
dysfunct
oxid
stress
inflamm
light
limit
efficaci
current
avail
treatment
option
pah
therapi
develop
novel
therapeut
strategi
need
regard
discoveri
seem
relev
discuss
shown
exert
host
benefici
effect
cardiopulmonari
system
result
prevent
pah
figur
thu
appear
genet
approach
increas
activ
andor
use
synthet
activ
may
repres
potenti
new
therapi
effect
treat
pah
work
support
nih
grant
hl
paper
particular
interest
publish
within
period
review
highlight
special
interest
outstand
interest
